TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15743422

Group type: EXPERIMENTAL
Intervention: Emdogain Gel (EMDgel)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcium hydroxide and sterile saline
Number of subjects: 18
Study: 14692305

Group type: EXPERIMENTAL
Intervention: Tibolone 5 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: ECE/MPA (equine conjugated estrogens 0.625 mg + medroxyprogesterone acetate 2.5 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: ECE/MPA
Number of subjects: 30
Study: 10820349

Group type: EXPERIMENTAL
Intervention: 1% 5-aminolevulinic acid (5-ALA) topical application after 60-90 minutes
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fluorescence spectroscopy after 60-90 minutes
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 1% 5-ALA
Number of subjects: 68
Study: 8014326

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 2685655

Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Sinemet
Number of subjects: 0
Study: 781882

Group type: EXPERIMENTAL
Intervention: Penicillin (20 mega-units daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30407276

Group type: EXPERIMENTAL
Intervention: ABT (135 mL of RBC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham transfusion (PLA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ABT (combined 135 mL and 235 mL of RBC)
Number of subjects: 9
Study: 28623895

Group type: EXPERIMENTAL
Intervention: Home-based exercise therapy (Ex group: 18 subjects) - brisk walking for 30 min per day for 12 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (C group: 18 subjects) - no exercise therapy guidance, only recorded daily steps
Number of subjects: 36
Study: 25631224

Group type: EXPERIMENTAL
Intervention: Monthly regular didactic lecture (Group 2)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Monthly interactive education workshop (Group 3)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Self-learning reading (Group 1)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Group 3
Number of subjects: 360
Study: 23711100

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study: 20527302

Group type: EXPERIMENTAL
Intervention: Two tests separated by interpolated tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: One test (control)
Number of subjects: 0
Study: 18280581

Group type: EXPERIMENTAL
Intervention: Antidepressant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16634995

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg daily
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 12785242

Group type: EXPERIMENTAL
Intervention: Intensive training of sit-to-stand and step-up exercises for four weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual rehabilitation programme without additional training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 10962547

Group type: COMPARATOR
Intervention: High dose methylprednisolone (HD MP)
Number of subjects: 0
Study: 9169953

Group type: EXPERIMENTAL
Intervention: 30 mg/day beta-carotene in enteral feeding
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (beta-carotene and placebo)
Number of subjects: 26
Study: 1494580

Group type: EXPERIMENTAL
Intervention: VRP 1 physiotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autogenic drainage (AD)
Number of subjects: 20
Study: 3992070

Group type: EXPERIMENTAL
Intervention: Hay fever treatments (specific treatments not detailed)
Number of subjects: 0
Study: 30111213

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no music intervention)
Number of subjects: 28
Study: 29265566

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine 0.2%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intermittent bolus of ropivacaine 0.2%
Number of subjects: 120
Study: 26067286

Group type: EXPERIMENTAL
Intervention: Conventional medical treatment plus respiratory physiotherapy for 3 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 54
Study: 25209122

Group type: COMPARATOR
Intervention: Mitchell's osteotomy (MO)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Chevron osteotomy (CO)
Number of subjects: 120
Study: 22554359

Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 20602884

Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet (SOS) laryngoscope
Number of subjects: 41

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (MDLS)
Number of subjects: 41
Study: 18076237

Group type: EXPERIMENTAL
Intervention: Intermittent aerobic exercise (1:1 minute at V(.‐)O2max)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise (90% of the anaerobic threshold velocity)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (rested state strength tests)
Number of subjects: 8
Study: 16250910

Group type: EXPERIMENTAL
Intervention: Offering study results in a postal questionnaire (788 participants)
Number of subjects: 1038

Group type: COMPARATOR
Intervention: Not offering study results in a postal questionnaire (250 participants)
Number of subjects: 1038
Study: 12386351

Group type: EXPERIMENTAL
Intervention: Uterine balloon therapy (UBT)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Rollerball ablation
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Total population (255 women)
Number of subjects: 255
Study: 9918905

Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholate (750 mg/d for 2 months)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ursodeoxycholate (750 mg/d for 2 months)
Number of subjects: 12
Study: 7669308

Group type: EXPERIMENTAL
Intervention: Cricoid pressure application
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no cricoid pressure)
Number of subjects: 50
Study: 1859038

Group type: EXPERIMENTAL
Intervention: Atropine sulfate in saline (AS/S) nasal spray
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 90
Study: 6885408

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Brief Psychotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Biofeedback plus Brief Psychotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting-list Control
Number of subjects: 24
Study: 31619181

Group type: EXPERIMENTAL
Intervention: SCC-BMS (ultrathin strut silicon-carbide coated cobalt-chromium bare-metal stent)
Number of subjects: 1526

Group type: COMPARATOR
Intervention: UC-BMS (older thin-strut uncoated cobalt-chromium bare-metal stent)
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: SCC-BMS
Number of subjects: 1526

Group type: COMPARATOR
Intervention: UC-BMS
Number of subjects: 1526
Study: 30567604

Group type: EXPERIMENTAL
Intervention: Structured and monitored Nutrition + Exercise intervention
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 242
Study: 26992740

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) delivered via home-based telemedicine (HBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE) delivered in-person
Number of subjects: 0
Study: 25211927

Group type: EXPERIMENTAL
Intervention: Combined therapy including local negative pressure and laser illumination (LLNP)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Monotherapy with LLNP
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination of LLNP with PDE5 inhibitors
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: LLNP methodology
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Post-therapy
Number of subjects: 62
Study: 23187979

Group type: EXPERIMENTAL
Intervention: Short motivational interview, barrier reduction, outpatient appointment established, reminders before scheduled appointment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard referral (telephone number for a mental health provider)
Number of subjects: 24
Study: 20568934

Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lumbar arthroplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: Anterior lumbar interbody fusion (control)
Number of subjects: 24
Study: 18028739

Group type: EXPERIMENTAL
Intervention: Highly purified human menopausal gonadotrophin (HP‐HMG)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 731

Group type: EXPERIMENTAL
Intervention: HP‐HMG
Number of subjects: 731

Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 731
Study: 16059716

Group type: EXPERIMENTAL
Intervention: Updated GHb levels
Number of subjects: 3539

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose levels
Number of subjects: 3539
Study: 12198700

Group type: EXPERIMENTAL
Intervention: Variceal band ligation (VBL)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Propranolol (PPL)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (ISMN)
Number of subjects: 172
Study: 9925136

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus BG2FO4, ingested twice per day for 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (non-omeprazole-treated)
Number of subjects: 42
Study: 8583783

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (48 pmol/kg/min for 15 min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 13
Study: 2197347

Group type: EXPERIMENTAL
Intervention: Intravenous penicillin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study: 510213

Group type: EXPERIMENTAL
Intervention: Prazosin (20 mg/d)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30992113

Group type: EXPERIMENTAL
Intervention: BD, ZOE, SSC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BD, RMGIC, SSC
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BD, SSC
Number of subjects: 40

Group type: COMPARATOR
Intervention: BD only (control)
Number of subjects: 40
Study: 27712970

Group type: EXPERIMENTAL
Intervention: Statistical model for protamine titration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fixed protamine‐heparin dose ratio (1:1)
Number of subjects: 60
Study: 25779948

Group type: EXPERIMENTAL
Intervention: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) with tigatuzumab
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) without tigatuzumab
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Presence of CTC cluster
Number of subjects: 52
Study: 23973144

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (average duration 12 weeks)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Total joint replacement surgery (3 months post-surgery)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Matched controls (n = 43)
Number of subjects: 113
Study: 22143911

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 380
Study: 19064977

Group type: EXPERIMENTAL
Intervention: Monitoring for lack of benefit in randomized clinical trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commonly used monitoring guidelines
Number of subjects: 0
Study: 17845379

Group type: EXPERIMENTAL
Intervention: Nutrition knowledge intervention (details not specified)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Highest 10% of nutrition knowledge score
Number of subjects: 177

Group type: COMPARATOR
Intervention: General population of older adults
Number of subjects: 177
Study: 14981605

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d orally)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11180005

Group type: EXPERIMENTAL
Intervention: Suberythemal dose of whole body irradiation from ultraviolet-A-emitting fluorescent tubes
Number of subjects: 7

Group type: COMPARATOR
Intervention: Matched control group of unirradiated individuals
Number of subjects: 7
Study: 9589815

Group type: EXPERIMENTAL
Intervention: Foscarnet (four doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zalcitabine (five doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Concomitant foscarnet (four doses) and zalcitabine (six doses)
Number of subjects: 12
Study: 7920609

Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide (0.5‐1.0 g/m2 body surface area) for 4 months, followed by bimonthly doses for 4 months and quarterly doses for 6 months
Number of subjects: 29

Group type: COMPARATOR
Intervention: Pulse methylprednisolone (10‐20 mg/kg weight) initially for 3 consecutive days and thereafter in the same intervals as cyclophosphamide
Number of subjects: 29
Study: 3279351

Group type: EXPERIMENTAL
Intervention: 400 micrograms Cabergoline
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 600 micrograms Cabergoline
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 800 micrograms Cabergoline
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29356864

Group type: EXPERIMENTAL
Intervention: Lure task (lures, targets, and neutral events presented)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard task (targets and neutral events only)
Number of subjects: 126
Study: 26364953

Group type: EXPERIMENTAL
Intervention: Bonemaster (BM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional plasma-sprayed hydroxyapatite (HA)
Number of subjects: 55
Study: 23994192

Group type: EXPERIMENTAL
Intervention: Active tDCS (2mA, 30-min, 10-daily sessions and two additional fortnight sessions)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo sertraline
Number of subjects: 102
Study: 23731168

Group type: EXPERIMENTAL
Intervention: Silodosin (8 mg/day, n=53)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Naftopidil (75 mg/day, n=44)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Silodosin (8 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Naftopidil (75 mg/day)
Number of subjects: 97
Study: 19996137

Group type: EXPERIMENTAL
Intervention: Blocking the tibial and common peroneal nerves individually using ultrasound distal to sciatic bifurcation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prebifurcation sciatic block
Number of subjects: 76
Study: 18173309

Group type: COMPARATOR
Intervention: NAA/Cho ratio in patients with diffuse TBI within the first 10 days after injury (1.59 ± 0.46)
Number of subjects: 25

Group type: COMPARATOR
Intervention: NAA/Cr ratio in patients with diffuse TBI within the first 10 days after injury (1.44 ± 0.21)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NAA/Cho ratio minimum values in patients (1.05 ± 0.44)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: NAA/Cr ratio minimum values in patients (1.05 ± 0.30)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of NAA/Cho and NAA/Cr reductions with outcomes at 6 months
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Recovery of NAA/Cho levels at 40 days postinjury in patients with good outcomes
Number of subjects: 25
Study: 16316872

Group type: EXPERIMENTAL
Intervention: Budesonide (200 to 1600 microg/d via Turbuhaler)
Number of subjects: 945

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (200 to 1600 microg/d via pressurized metered-dose inhaler)
Number of subjects: 945
Study: 10481519

Group type: EXPERIMENTAL
Intervention: Deformities of rib chest wall
Number of subjects: 33
Study: 8732323

Group type: EXPERIMENTAL
Intervention: Computerized decision support system (DSS) for lipid management
Number of subjects: 150000

Group type: COMPARATOR
Intervention: Control group (baseline data collection)
Number of subjects: 150000
Study: 1929311

Group type: EXPERIMENTAL
Intervention: Single-dose ofloxacin (400 mg)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg) once daily for 3 days
Number of subjects: 130

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (160:800 mg) twice daily for 7 days
Number of subjects: 130
Study: 6357014

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (2 ml)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ethanol (1.5 ml/kg, p.o.)
Number of subjects: 18
Study: 30579860

Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide (at-home bleaching protocol; 4h/d×7)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 40% hydrogen peroxide (in-office bleaching protocol; 20min×3)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Non-metallic stained lesions (G1, G2, G3)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Metallic stained lesions (G4, G5, G6)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (no bleaching treatment, G1 and G4)
Number of subjects: 126
Study: 28176424

Group type: EXPERIMENTAL
Intervention: PAP-guided HF therapy using the CardioMEMS™ HF system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PAP-guided HF therapy using the CardioMEMS™ HF system with estimated staff time included
Number of subjects: 0
Study: 28485289

Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency (MP RF)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Bipolar radiofrequency (BP RF)
Number of subjects: 71
Study: 25098195

Group type: EXPERIMENTAL
Intervention: Constant feedback group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intermittent feedback group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 21717119

Group type: EXPERIMENTAL
Intervention: Moderate exercise intensity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Heavy exercise intensity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Very heavy exercise intensity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Peak oxygen uptake (VO(2peak))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: VO(2) kinetics at any exercise intensity
Number of subjects: 13
Study: 19216650

Group type: EXPERIMENTAL
Intervention: Nicardipine prolonged-release implants (NPRIs)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no NPRIs)
Number of subjects: 18
Study: 17690922

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Access flap (AF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 41

Group type: COMPARATOR
Intervention: Interproximal sites
Number of subjects: 41
Study: 15372416

Group type: EXPERIMENTAL
Intervention: Intravenous ascorbic acid (IVAA) 100 mg after each dialysis session
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no IVAA)
Number of subjects: 61
Study: 11472293

Group type: EXPERIMENTAL
Intervention: Epidural washout with twice the volume of 2% mepivacaine (group 2x)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Epidural washout with four times the volume of 2% mepivacaine (group 4x)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no washout)
Number of subjects: 30
Study: 9671364

Group type: EXPERIMENTAL
Intervention: Enteral immunonutrition (IMN) Impact (Novartis Nutrition)
Number of subjects: 390
Study: 7851275

Group type: EXPERIMENTAL
Intervention: bezafibrate 400 mg/day for 4 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: pravastatin
Number of subjects: 28
Study: 2801640

Group type: EXPERIMENTAL
Intervention: Rotary electric toothbrush
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 40
Study: 1095630

Group type: EXPERIMENTAL
Intervention: Isobaric oxygenation (97% oxygen + 3% carbon dioxide)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Compressed air (control group)
Number of subjects: 7
Study: 30316113

Group type: EXPERIMENTAL
Intervention: Misattribution of arousal procedure
Number of subjects: 0
Study: 27014755

Group type: EXPERIMENTAL
Intervention: Coffee + polyethylene glycol + ascorbic acid (750 mL, twice)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyethylene glycol + ascorbic acid (1-L, twice)
Number of subjects: 0
Study: 24887797

Group type: EXPERIMENTAL
Intervention: Group 1 (range 0 mm)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Group 2 (range 5 mm)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Group 3 (range 10 mm)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Group 4 (range 15 mm)
Number of subjects: 628

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 628
Study: 22734483

Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver nylon wound dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 0
Study: 19875683

Group type: EXPERIMENTAL
Intervention: %CSA(<5)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: DL(CO) % predicted
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: %CSA(5-10)
Number of subjects: 79
Study: 18095148

Group type: EXPERIMENTAL
Intervention: rhuEpo targeting at Hb >= 13.0 g/dL
Number of subjects: 31
Study: 15380964

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 185

Group type: COMPARATOR
Intervention: Ciclosporin microemulsion
Number of subjects: 185
Study: 11153973

Group type: EXPERIMENTAL
Intervention: Sleep restriction therapy
Number of subjects: 22
Study: 9847656

Group type: EXPERIMENTAL
Intervention: Preemptive lumbar epidural morphine (2 to 4 mg during anesthetic induction)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Postincisional lumbar epidural morphine (2 to 4 mg upon excision of tissue)
Number of subjects: 20